Medincell (Medincell) ROCE % : -796.37% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Medincell ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medincell's annualized ROCE % for the quarter that ended in Sep. 2023 was -796.37%.

Medincell ROCE % Historical Data

The historical data trend for Medincell's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell ROCE % Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-71.76

-74.92

-48.31

-76.39

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial										-48.21	-99.63	-217.04	-	-796.37

Medincell ROCE % Calculation

Medincell's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-30.062	/	( ( (48.792 - 42.116)	+	(31.412 - 61.055) )	/ 2 )
	=	-30.062	/	( (6.676	+	-29.643)	/ 2 )
	=	-30.062	/	-11.4835
	=	261.78 %

Medincell's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	-12.292	/	( ( (31.412 - 61.055)	+	(53.884 - 21.154) )	/ 2 )
	=	-12.292	/	( ( -29.643	+	32.73 )	/ 2 )
	=	-12.292	/	1.5435
	=	-796.37 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

Medincell (OTCPK:MDCLF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medincell ROCE % Related Terms

Thank you for viewing the detailed overview of Medincell's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (Medincell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (OTCPK:MDCLF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MEDCL:France MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (Medincell) Headlines

From GuruFocus

Q2 2022 Medincell SA Earnings Call(English) Transcript

By GuruFocus Research • 03-05-2024